Mauro Cives
@cives_mauro
Followers
326
Following
668
Media
1
Statuses
241
Associate Professor of Medical Oncology at the University of Bari, Italy. Focused on NETs.
Bari, Puglia
Joined April 2020
RT @CureNETs: New NETRF-supported research is advancing our understanding of metastatic neuroendocrine tumors. Genome analysis uncovered th….
0
3
0
PRRT with 177Lu-dotatate will not be an option for the first-line treatment of higher G2 and G3 GEP-NET patients in the near future in Europe. The scientific community, regulatory authorities and pharmaceutical industries must partner to foster access to effective treatments.
3
4
17
RT @OncoThor: I try, often unsuccessfully, to not post while on vacation but this is just too important. Hot of the @adasarimd et al. press….
0
21
0
RT @altoubaht: Almost hereee! I hope you all enjoy listening as much as I enjoyed recording! .Launching July 7th! 🎧🎙️.
0
1
0
RT @netcancerday: 🔶Dr. Mauro Cives @cives_mauro : “Single-cell and single-nuclei sequencing technologies will help researchers in gaining a….
0
2
0
RT @Ja_Capdevila: 🔊🔊 Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors 🙌🏼 A new trea….
www.ipsen.com
0
12
0
RT @netcancerday: Dr. Mauro Cives @cives_mauro : “By exploring new NEN models, we will be able to test treatments in vitro before administe….
0
1
0
RT @OncoThor: I still get excited about good clinical papers! 😀I have been waiting for this one with much anticipation. For anyone takin….
0
13
0
RT @greeneannac: 📢 The deadline for the BTSI award has been extended to June 23rd, so there's more time to submit your NEN-focused applicat….
0
1
0
RT @netcancerday: Dr. Mauro Cives @cives_mauro : “Cancer vaccines are investigated also in the NEN field.” .✔️Watch this valuable presentat….
0
1
0
RT @CureNETs: We're proud to join @Chimeric to announce that CAR T-Cell Therapy has a Fast-Track designation by the FDA as a potential new….
netrf.org
(Boston, MA): The Neuroendocrine Tumor Research Foundation (NETRF) is proud to join Chimeric Therapeutics in announcing that CAR T-cell therapy using CHM CDH17 has been granted Fast Track Designation...
0
2
0
RT @Chimeric: Chimeric Therapeutics gains FDA fast-track approval for CHM CDH17 gastrointestinal cancer candidate | Media coverage by @Smal….
smallcaps.com.au
Chimeric Therapeutics (ASX: CHM) has received fast-track designation from the US Food and Drug Administration (FDA) for lead candidate CHM CDH17 to treat
0
3
0
RT @jsoriamd: Radioligand therapies harness the cytotoxic force of radiotherapy with molecular precision—emerging as a new strategy for can….
0
21
0
RT @greeneannac: 🚨 Calling all early-career NET researchers!. The Basic/Translational Science Investigator (BTSI) Award—funded by @CureNETs….
0
1
0
RT @VivekSubbiah: 🚨 Wow! #ASCO25 @ASCO was absolutely massive!.10 @NEJM papers published simultaneously 👉 all practice-changing studies !….
0
183
0
0
1
0
RT @netcancerday: 📌Watch the NEW NET research video on the INCA website: @cives_mauro Dr. Mauro Cives presents the latest updates in tran….
0
2
0
RT @netcancerday: 📢NEW insightful video on NET research on INCA website! .👏Thank you to Dr. Mauro Cives @cives_mauro for the latest updates….
0
4
0
We’re hiring! Join our lab to work on cutting-edge TCR-based therapies in neuroendocrine tumors (NETs). Passionate about immunotherapy and translational cancer research? Apply by April 17, 2025!.#Postdoc #Immunotherapy #CancerResearch #TCR #NETs #Hiring.
reclutamento.ict.uniba.it
E' indetta la procedura selettiva pubblica, per titoli e colloquio, per il conferimento di n. 1 contratto di ricerca, ai sensi dell' art. 22 della legge 240/2010, per il GSD 06/MEDS-09 e SSD MEDS-0...
1
8
16